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Abstract 
Background 
The impact of the utilisation of such e-health approaches, including mHealth (use of mobile 
phones and other wireless technology in the delivery of medical care) assessments of health 
parameters, or the use of decision aids and online risk calculators over time have not been 
previously described. The objective of this analysis is to assess the time trends in use of the 
CHADS2 and CHA2DS2VASc scores in e-health, and the geographical and specialty uptake of 
these scores, using data gleaned from a popular online clinical decision tool and medical 
reference, MDCalc.  We hypothesised that the change in use of the scores would reflect the 
changes in guidelines and trends in clinical practice. 
Results 
The CHA2DS2VASc score was the 20th most popular calculator in 2012, rising to the 2nd 
most popular calculator in 2018; the CHADS2 score showed the converse, dropping from no. 
3 to no. 22.   
Use of the CHA2DS2VASc scores particularly increased in the United States, Canada and 
Australia over time while the United Kingdom experienced a greater traffic share in 2015. 
The majority users of the CHADS2 and CHA2DS2VASc scores were primary care physicians, 
with cardiologists being in the minority; the proportion of cardiologists was greater outside 
USA, compared to within USA. 
Conclusion 
Over time, use of the CHA2DS2VASc score increased, while use of the CHADS2 score 
decreased.  The change in uptake could partly be related to introduction of guidelines 
recommending the use of the CHA2DS2VASc score for stroke risk stratification. 
 
Key words  Stroke risk, CHA2DS2VASc, CHADS2 Score, risk calculator, clinical decision tool, e-
health, mhealth 
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What is already known about this topic? 
 
 Medical decision making is increasingly influenced by electronic-health (e-health) 
information technology approaches, including mHealth assessments of health parameters, 
or the use of decision aids and online risk calculators. 
 
What does this article add? 
 
 Over time, use of the CHA2DS2VASc score increased, while use of the CHADS2 score 
decreased.  The change in uptake could partly be related to introduction of guidelines 
recommending the use of the CHA2DS2VASc score for stroke risk stratification. 
 
1. Introduction 
Medical decision making is increasingly influenced by electronic-health (e-health) 
information technology approaches, including mHealth assessments of health parameters, 
or the use of decision aids and online risk calculators(1).  The impact of ultilisation of such e-
health techniques over time have not been previously described. 
Take the case of the management of atrial fibrillation (AF), the most common heart rhythm 
disorder, whereby stroke prevention is the cornerstone of management(2).  AF is commonly 
managed by general practitioners and non-cardiologists, and over the last two decades we 
have seen the introduction of stroke risk stratification schemes, such as the CHADS2 score 
(June 2001) and more latterly, the CHA2DS2VASc score (September 2009), to aid decision-
making for thromboprophylaxis(2).  Most guidelines initially recommended the use of the 
CHADS2 score but with increasing data on improved refinement of stroke risk assessment, 
beginning in 2012 the CHA2DS2VASc score became more recognized by medical societies and 
is now recommended in most guidelines from the United States, Europe, and Asia (3-5). 
The objective of this analysis is to assess the time trends in use of the CHADS2 and 
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CHA2DS2VASc scores in e-health, and the geographical and specialty uptake of these scores, 
using data gleaned from a popular online clinical decision tool and medical reference, 
MDCalc.  We hypothesised that the change in use of the scores would reflect the changes in 
guidelines and trends in clinical practice. 
 
2. Methods 
2.1. Study Design 
A retrospective study was carried out using usage data from a popular online clinical 
decision tool and medical reference, MDCalc. Authors of this manuscript include a founder 
and part owner of MDCalc, as well as employees and advisors of MDCalc.  The latter was 
first introduced in 2005, and is the first natural search result to appear for most terms used 
to find CHADS2 and CHA2DS2VASc scores. Data analyzed were from MDCalc’s web and app 
usage and registration databases, provided by MD Aware LLC. The authors hypothesised 
that analysis of such data can measure and possibly predict the update of clinical tools over 
time. The study investigated data obtained using Google Analytics on the CHA2DS2-VASc 
Score for Atrial Fibrillation Stroke Risk (CHA2DS2-VASc Score), the CHADS2 Score for Atrial 
Fibrillation Stroke Risk (CHADS2 Score), and a normalization group of scores from January 1, 
2012 to April 30, 2018.  
2.2. Analytics Platform 
Data were collected for visits to the mdcalc.com website and MDCalc iOS and Android apps 
in one month intervals using the statistics tool Google Analytics. The relevant Google 
Analytics metrics used in this study include:  
 
 
 
 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
User 
This Google Analytics metrics attempts to count how many unique individuals access 
MDCalc in a given time. Specifically, it’s typically tracked using an “electronic cookie” that’s 
managed by Google Analytics.1 
 
Geographical Data 
Google Analytics provides a number of geographical dimensions, such as City, Country, 
Continent, and more. The values for these dimensions are automatically derived from the IP 
address of the computer or mobile device used.2 
2.3. Data Collection and Processing  
In this study, data were collected for Users, specific MDCalc pages (calculators) visited, 
geographical data (country) in the Google Analytics servers and, for registered Users, 
registration data were collected in the MDCalc User Database. Anonymized data were 
exported from Google Analytics and the MDCalc User Database as .csv files and compiled in 
Microsoft Excel for further analysis and visualization.  
 
User Adoption 
The data were examined in two groups, (i) Users who visited the CHA2DS2-VASc Score, and 
(ii) Users who visited the CHADS2 Score. The data for both groups were normalized as 
explained in the following section. MDCalc did not specifically promote either CHADS2 or 
CHA2DS2-VASc Scores during the study period. 
 
 
                                                             
1 https://support.google.com/analytics/answer/2992042?hl=en&ref_topic=2709827 
2 https://support.google.com/analytics/answer/6160484?hl=en 
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Normalization 
Medical calculator and reference popularity has risen dramatically over the last decade as 
technology is increasingly adopted in the clinician workflow. In addition, with time, 
physicians have become more tech savvy and more evidence based, both of which have led 
to a large increase in the usage of EBM electronic medical references such as MDCalc. 
Therefore, in order to capture the relative use and popularity of specific scores,  data must 
be normalized to account for these trends. The approach to normalization also took into 
account that sometimes specific calculators are replaced by newer calculators – for 
reference in the last four years, MDCalc has gone from 80 to 370 calculators with over 600 
scores in the pipeline. The Normalization Group was chosen by identifying scores that 
ranked, in order of most visits, in the top 25 from January 1, 2012 to February 28, 2012 that 
also ranked in the top 50 from January 1, 2018 to February 28, as described in Table 1. This 
approach attempted to capture the the overall trend in increased MDCalc use, while 
removing specific calculators which may have been popular in 2012 but had a large drop in 
use by 2018, and therefore not be useful in normalization. Of note, only 2 calculators of the 
“top 25” in 2012 fell off the “top 50” by 2018 – the other 23 are listed in Table 1.  The 
aforementioned time periods were chosen for two reasons: first, both scores were available 
on MDCalc during these periods, second, the 2012 ESCG Guidelines for the management of 
AF (the first major guideline formally recommending the CHA2DS2-VASc Score) had not yet 
been published. 
 
Per Country Adoption 
In order to evaluate when the CHA2DS2-Vasc Score and the CHADS2 Score were adopted in 
specific countries, per country User data from Google Analytics for March of 2012, 2015, 
and 2018 was normalized by the average of the Normalization Group in each country and 
was mapped (Figure 3) with a constant maximum and minimum. MDCalc has been available 
globally, in English, since 2005. 
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Per Specialty Adoption 
User specialty data are available on Google Analytics for logged in Users, a requirement for 
the iOS and Android app. For Users who visited the CHA2DS2-Vasc Score, User specialties, as 
reported by Users at registration, were collected for both the U.S. and Ex-U.S. (Figure 4) and 
compared with relative specialty representation amongst iOS and Android app Users in the 
MDCalc User Database.  
3. Results 
From January 1, 2012 to February 28, 2012 the CHA2DS2-VASc Score was ranked the 20th 
most popular calculator on MDCalc and the second most popular calculator from January 1, 
2018 to February 28, 2018. For those same time periods, the CHADS2 Score ranked no. 3 and 
no. 22, respectively – the Normalization Group average rank was 12.3 and 21.7, 
respectively. 
3.1. General Usage of CHA2DS2-VASc Score 
The CHA2DS2-VASC Score had a peak of 109,347 Users in February 2018, surpassing the 
CHADS2 Score monthly Users from December 2012 to April 2018, with the exception of 
December 2013 (Figure 1). A seasonal variation was observed around the November and 
December holidays and during the month of June. In 2018 the average number of monthly 
users for the CHA2DS2-VASC Score was 2.96 times greater and the CHADS2 Score was .076 
times greater than the top 25 scores (p<0.0001). 
 
The normalized (2012) data, fig. 2, reveals that the CHA2DS2-VASC Score had two intervals of 
peak growth from September 1, 2012 to January 31, 2013 and February 1, 2014 to October 
31, 2014. There is be both a decrease in Users who used the CHA2DS2-VASC Score, 17.3%, 
and an increase, 85.9%, in Users who used the CHADS2 Score in February and March, 2017.  
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We noted an inconsistent drop in CHA2DS2-VASc Score use starting around February 2017, 
with a correlated increase in CHADS2 use, which seemed to return to trend line after April 
2017 (Figure 1). Analyzing the search terms used for users landing on such pages for these 
same months, a large number of users landing on the CHADS2 page had actually searched 
for “CHA2DS2-VASC Score” (Figure 2, Panel 2). This would suggest this Feb-April 2017 change 
in usage was more likely due to Google search result changes, not in purposeful change in 
use by users: i.e. users mistakenly clicking on the CHADS2 page as it temporarily appeared 
high up in their “CHA2DS2-VASc Score” search. 
 
3.2. Per Country Adoption of CHA2DS2-VASc Score 
User data per country, normalized to 2012, are shown in a series of geographical heat maps 
(Figure 3) at three time intervals, March 2012, 2015 and 2018.  
 
The CHA2DS2-VASc Score normalized (2012), (Figure 3, Panel 1) showed an increase in 
relative Users in the United States, Canada and Australia over time while the United 
Kingdom experienced a greater traffic share in 2015 than 2018, with the least traffic share in 
2012. Conversely, the CHADS2 Score (Figure 3, Panel 2) experienced a decrease in relative 
Users in the United States, Australia and the United Kingdom over time while Canada 
experienced a greater traffic share in 2015 than 2018, with the least traffic share in 2012. 
The sharp increase in normalized use of the CHA2DS2-VASc Score in UK from 2012 to 2015, 
with a relative decrease in 2018, may represent how MDCalc was relatively new to the U.K. 
in those years, and that the CHA2DS2-VASc Score led in terms of UK’s physicians’ use of 
MDCalc scores in 2015 – perhaps due to the 2014 NICE guidelines which included the score. 
This limited analysis was meant only to screen for broad country specific trends. An 
interesting further area of research may include a more detailed analysis of per country 
adoption, including data at more time intervals, details on when guidelines and other 
relevant local authorities promoted scores, and potential normalizations tailored to each 
country. 
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3.3. Per Specialty Adoption of CHA2DS2-VASc and CHADS2 Scores 
The CHA2DS2-VASc Score and CHADS2 Scores were used most frequently by primary care 
providers and then cardiologists, both in the United States and outside of the United States 
(Figure 4, Panel 1). Taking into consideration that some specialties are larger than others, 
the percentage of specialists who use CHA2DS2-VASc and CHADS2 Scores on MDCalc were 
graphed in Figure 4, Panel 2, showing that more cardiologists who use MDCalc use those 
scores, particularly the CHA2DS2-VASc, were outside of the United States.  
4. Discussion 
In this analysis, our principal findings are as follows: (i) the CHA2DS2VASc score was the 20
th 
most popular calculator in 2012, and rose to become the 2nd most popular calculator; the 
CHADS2 Score showed the converse, dropping from no. 3 to no. 22; (ii) Use of the 
CHA2DS2VASc scores increased in the United States, Canada and Australia over time while 
the United Kingdom experienced a greater traffic share in 2015; and (iii) the majority users 
of the CHADS2 and CHA2DS2VASc scores were primary care physicians, with cardiologists 
being in the minority.  Interestingly, the proportion of cardiologists was greater outside USA, 
compared to within USA. 
 
This is the first systematic analysis of trends in e-health usage of two stroke risk scores for 
stroke prevention in AF, the CHADS2 and CHA2DS2VASc scores.  The increasing use of 
CHA2DS2VASc score in the USA is clearly evident from the marked change in heat maps 
(Figure 3), especially following the publication of the ACC/AHA/HRS guidelines in 2014(3).  
The increase in the UK in 2015, may reflect the new NICE guidelines, which recommended 
use of the CHA2DS2VASc score(6).  Guideline change per se need not necessarily translate to 
more e-health use, as the Canadian guidelines do not recommend the CHA2DS2VASc score, 
but CHADS65 or the CCS algorithm(7).  Also, the Asia-Pacific guidelines recommend the 
CHA2DS2VASc score but MDCalc uptake was limited in the Asia-Pacific region, which could 
partly reflect accessibility(5). 
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In a recent survey of European arrhythmia practitioners conducted by the European Heart 
Rhythm Association (EHRA), 98.3% used the CHA2DS2VASc score for stroke risk stratification; 
the remainder (1.7%) used the older CHADS2 score(8).  This is perhaps unsurprising given the 
European guidelines recommend use of the CHA2DS2VASc score(4). 
 
There are many interesting findings, some of which could be investigated further and 
potentially acted upon. For example, how quickly do physicians adopt new, better clinical 
scores after (a) the evidence shows they may be superior, and (b) after medical societies 
and guidelines promote their use? Has such adoption delay shortened over the years, and if 
so, what factors have shortened it. How effective is acceptance by medical societies and 
guidelines to driving adoption?  Can electronic medical references also help speed along 
adoption, and by how much?  Does this vary across physician populations (by age, 
geography, or specialty)? 
 
More specific to medical references, can changes in their design, or even in Google search 
results, effect how physicians practice (see the “bump” in CHADS2 use in early 2017, likely 
due to temporary google search changes). What can be implemented to mediate this? 
Finally, how do clinical outcomes with specific patient populations in specific countries 
correlate with the use of clinical scores in those countries? Such analysis may help quantify 
the relative benefit of a new score over old standard of care practice, which could have an 
impact not only on how physicians apply the scores, but also on how researchers spend 
their time, what grant administrators decide to fund to have the most clinical impact, and 
how payers and providers decide to value the proper use of clinical scores.  
Limitations 
Using cookies allows analytics.js to identify unique users across browsing sessions, but it 
cannot identify unique users across different browsers or devices.3  The specialty data is 
only app data (which were missing from March 3/2016 to 2/2017) although overall trends 
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for specialty use should be a reasonable representation of users.  In some countries, the lack 
of data does not necessarily mean no usage, but lack of access may be a factor. 
 
Conclusion 
Over time, use of the CHA2DS2VASc score increased, while use of the CHADS2 score 
decreased.  The change in uptake could partly be related to introduction of guidelines 
recommending the use of the CHA2DS2VASc score for stroke risk stratification. 
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Table 1 
Normalization Group 
 Score Jan-Feb 2012 
Rank* 
Jan-Feb 2018 
Rank* 
1 Creatinine Clearance (Cockcroft-Gault Equation) 1 1 
2 Wells' Criteria for Pulmonary Embolism 2 3 
3 CHADS2 Score for Atrial Fibrillation Stroke Risk 3 22 
4 Calcium Correction for Hypoalbuminemia 4 5 
5 Fractional Excretion of Sodium (FENa) 5 8 
6 TIMI Risk Score for UA/NSTEMI 6 25 
7 Corrected QT Interval (QTc) 7 11 
8 Framingham Coronary Heart Disease Risk Score 8 23 
9 MELD Score (Model For End-Stage Liver Disease) (12 and 
older) 
9 7 
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10 A-a O2 Gradient 10 48 
11 Fractional Excretion of Urea (FEUrea) 11 38 
12 APACHE II Score 12 44 
13 Wells' Criteria for DVT 13 19 
14 Parkland Formula for Burns 14 43 
15 MDRD GFR Equation 15 18 
16 Maintenance Fluids Calculations 16 20 
17 Absolute Neutrophil Count (ANC) 17 26 
18 PERC Rule for Pulmonary Embolism 18 14 
19 CHA2DS2-VASc Score for Atrial Fibrillation Stroke Risk 20 2 
20 Anion Gap 21 30 
21 ABCD2 Score for TIA 22 36 
22 Maddrey's Discriminant Function for Alcoholic Hepatitis 23 45 
23 HAS-BLED Score for Major Bleeding Risk 25 12 
*Rank was based on visits 
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Fig. 1 
Panel 1: Absolute Users per month, not normalized 
 
 
Panel 2: Users per month, normalized (2012) 
 
  
           
Fig. 2 
Panel 1: Landing page traffic source 
 
 
Panel 2: CHADS2 landing page – organic search terms 
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Fig. 3.  
Panel 1: CHA2DS2-VASc Score, normalized (2012), Users per country 
A) March 2012 
 
B) March 2015 
 
C) March 2018 
 
 
Panel 2: CHADS2 Score, normalized (2012), Users per country 
A) March 2012 
 
B) March 2015 
 
C) March 2018 
 
 
Panel 3: CHA2DS2-VASc Score and CHADS2 Score, per country, 2012, 2015 & 2018. 
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Fig. 4 
Panel 1: Portion of total CHA2DS2-Vasc Usage by 
Specialist (2018). 
 
 
Panel 2: Portion of each specialty group that used 
CHA2DS2-Vasc in the past month (2018). 
 
 
 
 
